Chronic erythropoietin treatment enhances endogenous nitric oxide production in rats

Scandinavian Journal of Clinical and Laboratory Investigation

Volumn 57, Issue 6, 1997, Pages 487-493

  Tsukahara, H ^a   Hiraoka, M ^a   Hori, C ^a   Hata, I ^a   Okada, T ^a   Gejyo, F ^a   Sudo, M ^a  

^a UNIVERSITY OF FUKUI   (Japan)

Author keywords

Endogenous nitric oxide activity; Hypertension; Nitric oxide synthase inhibitors; NO2 and NO3 ; Recombinant human erythropoietin

Indexed keywords

AMINOGUANIDINE; ARGININE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE INHIBITOR; RECOMBINANT ERYTHROPOIETIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DOSE RESPONSE; ENZYME ACTIVATION; HEMATOCRIT; HYPERTENSION; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRESSOR RESPONSE; PRIORITY JOURNAL; RAT; SUBCUTANEOUS DRUG ADMINISTRATION; SYSTOLIC BLOOD PRESSURE;

EID: 0030760293     PISSN: 00365513     EISSN: None     Source Type: Journal    
DOI: 10.3109/00365519709084598     Document Type: Article

References (26)

1. Eschbach JW, Egrie JC, Downing MR, Browne JK, Adamson JW. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. N Engl J Med 1987; 316: 73-8.
2. Carlini R, Obialo CI, Rothstein M. Intravenous erythropoietin (rHuEPO) administration increases plasma endothelin and blood pressure in hemodialysis patients. Am J Hypertens 1993; 6: 103-7.
3. Tepel M, Wischniowski H, Zidek W. Erythropoietin increases cytosolic free calcium concentration and thrombin induced changes in cytosolic free calcium in platelets from spontaneously hypertensive rats. Biochem Biophys Res Commun 1991; 177: 991-7.
4. Heidenreich S, Rahn KH, Zidek W. Direct vasopressor effect of recombinant human erythropoietin on renal resistance vessels. Kidney Int 1991; 39: 259-65.
5. Muntzel M, Hannedouche T, Lacour B, Drücke T. Effect of erythropoietin on hematocrit and blood pressure in normotensive and hypertensive rats. J Am Soc Nephrol 1992; 3: 182-7.
6. Carlini RG, Dusso AS, Obialo CI, Alvarez UM, Rothstein M. Recombinant human erythropoietin (rHuEPO) increases endothelin-1 release by endothelial cells. Kidney Int 1993; 43: 1010-14.
7. Caravaca F, Pizarro JL, Arrobas M, Cubero JJ, García MC, Perez-Miranda M. Antiplatelet therapy and development of hypertension induced by recombinant human erythropoietin in uremic patients. Kidney Int 1994; 45: 845-51.
8. Kato K, Mizuno K, Hashimoto S, Okazaki K, Asahi K, Kuriki M, et al. Direct evidence for erythropoietin-induced release of endothelin from peripheral vascular tissue. Life Sci 1994; 54: 253-9.
9. Martin J, Moncada S. Blood pressure, erythropoietin, and nitric oxide. Lancet 1988; 1: 644.
10. Marsden PA, Goligorsky MS, Brenner BM. Endothelial cell biology in relation to current concepts of vessel wall structure and function. J Am Soc Nephrol 1991; 1: 931-48.
11. Moncada S, Higgs A. Mechanisms of disease: the L-arginine-nitric oxide pathway. N Engl J Med 1993; 329: 2002-12.
12. Wilcox CS, Deng X, Doll AH, Snellen H, Welch WJ. Nitric oxide mediates renal vasodilation during erythropoietin-induced polycythemia. Kidney Int 1993; 44: 430-5.
13. Jia L, Bonaventura C, Bonaventura J, Stamler JS. S-nitrosohaemoglobin: a dynamic activity of blood involved in vascular control. Nature (London) 1996; 380: 221-6.
14. Wennmalm Å, Benthin G, Edlund A, Jungersten L, Kieler-Jensen N, Lundin S, et al. Metabolism and excretion of nitric oxide in humans: an experimental and clinical study. Circ Res 1993; 73: 1121-7.
15. Bank N, Aynedjian HS. Role of EDRF (nitric oxide) in diabetic renal hyperfiltration. Kidney Int 1993; 43: 1306-12.
16. Baylis C, Mitruka B, Deng A. Chronic blockade of nitric oxide synthesis in the rat produces systemic hypertension and glomerular damage. J Clin Invest 1992; 90: 278-81.
17. Fujihara CK, Michellazzo SM, DeNucci G, Zatz R. Sodium excess aggravates hypertension and renal parenchymal injury in rats with chronic NO inhibition. Am J Physiol 1994; 266 (Renal Fluid Electrolyte Physiol 35): F697-F705.
18. Grisham MB, Specian RD, Zimmerman TE. Effects of nitric oxide synthase inhibition on the pathophysiology observed in a model of chronic granulomatous colitis. J Pharmacol Exp Ther 1994; 271: 1114-21.
19. Tsukahara H, Miura M, Tsuchida S, Hata I, Hata K, Yamamoto K, et al. Effect of nitric oxide synthase inhibitors on bone metabolism in growing rats. Am J Physiol 1996; 270 (Endocrinol Metab 33): E840-E845.
20. Misko TP, Moore WM, Kasten TP, Nickols GA, Corbett JA, Tilton RG, et al. Selective inhibition of the inducible nitric oxide synthase by aminoguanidine. Eur J Pharmacol 1993; 233: 119-25.
21. G-nitro-L-arginine, and aminoguanidine on constitutive and inducible nitric oxide synthase in rat aorta. Biochem Biophys Res Commun 1994; 199: 147-54.
22. Takita M, Oda Y, Kigoshi S, Muramatsu I. Effects of propranolol and atenolol on immobilization stress-induced hypertension and downregulation of central beta-adrenoceptors in rats. Pharmacol Biochem Behav 1995; 50: 225-32.
23. Ranjan V, Xiao Z, Diamond SL. Constitutive NOS expression in cultured endothelial cells is elevated by fluid shear stress. Am J Physiol 1995; 269 (Heart Circ Physiol 38): H550-H555.
24. Korenaga R, Ando J, Tsuboi H, Yang W, Sakuma I, Toyo-oka T, et al. Laminar flow stimulates ATP- and shear stress-dependent nitric oxide production in cultured bovine endothelial cells. Biochem Biophys Res Commun 1994; 198: 213-19.
25. Sessa WC, Pritchard K, Seyedi N, Wang J, Hintze TH. Chronic exercise in dogs increases coronary vascular nitric oxide production and endothelial cell nitric oxide synthase gene expression. Circ Res 1994; 74: 349-53.
26. Poston L, Taylor PD. Endothelium-mediated vascular function in insulin-dependent diabetes mellitus. Clin Sci 1995; 88: 245-55.